Lapatinib Shows Minimal Effect Against Liver Cancer
Tuesday, September 8, 2009 - 12:35
in Health & Medicine
1) Lapatinib only benefited a subgroup of patients who developed a rash from toxicity; 2) Hepatocellular carcinomas are clinically, biochemically heterogeneous; 3) Drug was well-tolerated overall; 12 percent required a dose reduction.